Elucid Appoints Dr. Michael Lesh to Board of Directors

BOSTON--(BUSINESS WIRE)-- Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221103005598/en/

Michael D. Lesh, MD, FACC, new member of the Elucid, Inc. Board of Directors. Source: Elucid, Inc.

“We look forward to what Dr. Lesh will bring to the board with his extensive background as a cardiologist, medtech executive, and technological innovator. His vast experience and proven track record will greatly support Elucid’s continued work in combating cardiovascular disease,” said Blake Richards, chief executive officer, Elucid.

Dr. Lesh is currently CEO and founder of Syntegra, a company focused on privacy-preserved synthetic data that bridges the gap between an organization’s data privacy and data science needs. He is also executive chairman of Cordance Medical, a company revolutionizing treatment of cancer, Alzheimer’s disease, and other brain disorders using non-invasive transcranial focused ultrasound to temporarily open the blood-brain-barrier. Dr. Lesh is a Professor of Medicine and former Chief of Cardiac Electrophysiology at University of California, San Francisco (UCSF). Dr. Lesh has a background in biomedical engineering and computer science from MIT. He received his medical training at UCSF and University of Pennsylvania. Dr. Lesh is the author of over 200 scientific papers, book chapters, and books, and is an inventor on over 250 patents.

“I am honored to bring my experience as a cardiologist and inventor entrepreneur to the Elucid board during this time of rapid growth for Elucid and the cardiac imaging field,” said Dr. Lesh. “The Elucid technology is poised to become the standard of care for non-invasive diagnosis of cardiovascular disease, and I look forward to working with the company to make this a reality.”

About Elucid

Elucid is a Boston-based medical technology company that has developed a non-invasive image analysis software designed to deeply understand the biology of cardiovascular disease. Elucid’s patented PlaqueIQ™ technology is the only FDA-cleared and CE-marked analysis software that objectively quantifies plaque morphology validated against tens of thousands of tissue samples and, with an investigational tool, derives FFR_CT from these plaque measurements. Advanced clinical insights from Elucid equip physicians with critical information designed to enable precision medicine for both assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke, as well as assessing blockages to determine the need for revascularization. The Elucid Plaque Analysis software is available for commercial use in the U.S., Europe and South Korea. For more information, visit elucid.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005598/en/